VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
VBIV was delisted on the 7th of August, 2024.
20 hedge funds and large institutions have $27.6M invested in VBI Vaccines, Inc. New Common Stock (Canada) in 2016 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 5 increasing their positions, 2 reducing their positions, and 4 closing their positions.
150% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 2
25% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 4
5% more funds holding
Funds holding: 19 → 20 (+1)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
7% less capital invested
Capital invested by funds: $29.7M → $27.6M (-$2.02M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Cambridge Investment Research Advisors
Fairfield,
Iowa
|
+$1.26M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$573K |
| 3 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$179K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$61.8K |
| 5 |
Renaissance Technologies
New York
|
+$53.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Neuberger Berman Group
New York
|
-$26K |
| 2 |
KA
Klingman & Associates
New York
|
-$19K |
| 3 |
TWA
TCI Wealth Advisors
Tucson,
Arizona
|
-$10K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$9K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$2.47K |
VBIV Hedge Fund Activity: Q3 2016 in Review
20 of the 3,759 institutional investors tracked by Wall St. Rank reported a position in VBI Vaccines, Inc. New Common Stock (Canada) (VBIV) for Q3 2016, worth a combined $27.6M — down 6.8% from $29.7M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new VBIV positions and 4 closed out — a net gain of 1 holder — while 5 added to existing stakes and 2 trimmed.
The largest buyer was Cambridge Investment Research Advisors, adding an estimated $1.26M. The largest seller was Neuberger Berman Group, exiting entirely with an estimated $26K sold.
- 20 institutional investors held VBI Vaccines, Inc. New Common Stock (Canada) (VBIV) as of Q3 2016, up from 19 in Q2 2016.
- Funds reported $27.6M of VBI Vaccines, Inc. New Common Stock (Canada) stock for Q3 2016, down 6.8% quarter-over-quarter.
- 5 funds opened new VBI Vaccines, Inc. New Common Stock (Canada) positions in Q3 2016 and 4 closed out, a net change of +1 holder.
- The largest VBI Vaccines, Inc. New Common Stock (Canada) buyer in Q3 2016 was Cambridge Investment Research Advisors, an estimated $1.26M added.
- The largest VBI Vaccines, Inc. New Common Stock (Canada) seller in Q3 2016 was Neuberger Berman Group, an estimated $26K sold.
Based on aggregated 13F filings for Q3 2016.